HC Wainwright Has Positive Outlook for PolyPid Q2 Earnings

PolyPid Ltd. (NASDAQ:PYPD) – Stock analysts at HC Wainwright lifted their Q2 2026 earnings per share (EPS) estimates for shares of PolyPid in a report issued on Tuesday, July 21st. HC Wainwright analyst B. Folkes now forecasts that the company will earn ($0.36) per share for the quarter, up from their prior forecast of ($0.38). HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($0.77) per share. HC Wainwright also issued estimates for PolyPid’s Q3 2026 earnings at ($0.40) EPS, Q4 2026 earnings at ($0.51) EPS, FY2026 earnings at ($1.63) EPS, FY2027 earnings at ($0.84) EPS, FY2028 earnings at ($0.40) EPS, FY2029 earnings at $0.80 EPS and FY2030 earnings at $1.64 EPS.

PYPD has been the topic of a number of other reports. Craig Hallum set a $12.00 target price on shares of PolyPid in a report on Wednesday. Weiss Ratings raised shares of PolyPid from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 23rd. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $11.33.

PolyPid Price Performance

Shares of NASDAQ PYPD opened at $3.90 on Thursday. The company has a 50 day simple moving average of $4.84 and a 200 day simple moving average of $4.58. The firm has a market cap of $74.41 million, a PE ratio of -2.04 and a beta of 1.40. PolyPid has a 1 year low of $3.06 and a 1 year high of $5.73.

PolyPid (NASDAQ:PYPD) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.12.

Institutional Investors Weigh In On PolyPid

Several institutional investors and hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets lifted its stake in shares of PolyPid by 56.1% in the third quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock worth $32,000 after acquiring an additional 3,500 shares during the period. HighTower Advisors LLC acquired a new stake in PolyPid during the 4th quarter valued at approximately $44,000. Jane Street Group LLC acquired a new stake in PolyPid during the 4th quarter valued at approximately $66,000. Renaissance Technologies LLC bought a new position in PolyPid during the 1st quarter worth approximately $81,000. Finally, XTX Topco Ltd raised its holdings in PolyPid by 50.0% during the 4th quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock worth $142,000 after purchasing an additional 10,888 shares during the last quarter. Institutional investors and hedge funds own 26.47% of the company’s stock.

PolyPid News Roundup

Here are the key news stories impacting PolyPid this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating on PolyPid and maintained a $13 price target, signaling continued confidence in the stock’s longer-term potential. The firm also slightly raised its Q2 2026 EPS estimate and Q4 2026 EPS estimate, which may help support sentiment. Article Title
• Neutral Sentiment: HC Wainwright made several forecast adjustments for future years, with some estimates improving and others declining. The changes suggest analysts still see meaningful uncertainty in PolyPid’s earnings path, but not a major shift in the overall investment thesis.
• Negative Sentiment: Short interest in PolyPid (PYPD) rose sharply in July to 283,206 shares, up 235.2% from late June, with about 2.0% of shares sold short. Rising short interest can indicate growing skepticism among traders and may weigh on the stock. Article Title
• Negative Sentiment: HC Wainwright cut its FY2027, FY2028, FY2029, and FY2030 EPS estimates for PolyPid, including a sizeable reduction to FY2030 expectations. Lower long-term earnings forecasts can pressure valuation expectations, even though the firm kept its bullish rating. Article Title

About PolyPid

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.